HealthcareNasdaq
Institutional-grade research for retail investors
SEC EDGAR: CIK 888721TRIB stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 26 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

TRIB Stock Analysis & AI Quality Score

AI stock analysis and institutional research for TRINITY BIOTECH PLC (TRIB), a Healthcare sector company. TRIB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 26 institutional filers currently hold this stock. Based on the latest XBRL financial filings (FY 2024), TRINITY BIOTECH PLC reports quarterly revenue of $61.6M, net income of $-31.2M. Top institutional holders of TRIB by reported 13-F value include Yorkville Advisors Global,, Williams & Novak,, Moss Adams Wealth Advisors, based on the most recent SEC filings. TRIB trades on the Nasdaq exchange and files with the SEC under CIK 888721. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TRIB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TRINITY BIOTECH PLC directly from SEC EDGAR.

Revenue

FY 2024

$61.6M

Net Income

FY 2024

$-31.2M

AI Insight: TRIB Ratio Trends

No financial ratio data available for Trinity Biotech across all periods — insufficient information to assess operational performance trends.

All key profitability and efficiency metrics missing across nine periods from Q4 2019 through Q4 2024.

Complete absence of ratio data prevents assessment of operational leverage, capital efficiency, or financial health trends.

Get alerted when TRIB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TRINITY BIOTECH PLC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put TRIB on your watchlist

Track score changes the day TRINITY BIOTECH PLC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is TRIB a good stock to buy?

13F Pro's AI-powered analysis of TRINITY BIOTECH PLC (TRIB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TRIB are available on the TRIB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TRIB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TRIB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TRINITY BIOTECH PLC's investment landscape.